Substance | Author(s) | Year | Study type | N | tumour | RT dose/ChTx/technique | Toxicity |
---|---|---|---|---|---|---|---|
Thalidomide | Knisely et al. [93] | 2008 | Phase III | 332 (90 thalidomide) | Brain metastases | 37,5 Gy (2,5 Gy) | 53% interruptions because of side-effects |
 | Chang et al. [187] | 2004 | Phase II | 67 | GBM | 60 Gy (2 Gy), TMZ concomitant | 10% grade III + IV neutropenia, 1% grade V; 16% grade III + IV thrombopenia, 9% grade III + IV rash, 1% grade III constipation, 9% grade III fatigue |
 | Atkins et al. [188] | 2008 | Phase II | 39 | CNS metastases (melanoma) | 30 Gy (3 Gy) WBRT + TMZ concomitant | 10% grade III + IV + V thrombosis, 5% grade III + IV + V myelosuppression, 8% grade III + IV + V cardiac events |
 | Ch'ang et al. [189] | 2011 | Phase II | 24 | HCC | 50 Gy (2 Gy) | 54% rash, 38% somnolence, 33% constipation |
 | Turner et al. [97] | 2007 | Phase II | 13 | Brainstem glioma + GBM | 55.8 Gy (1.8 Gy) | 8% grade IV DVT, ≥ 15% grade III leukopenia/motoneuropathy/constipation |
Lenalidomide | Drappatz et al. [101] | 2009 | Pilot study | 23 | GBM | 60 Gy (2 Gy) | 4% grade IV pneumonitis/hypoxia, 9% grade III nausea, 4% grade IV pulmonary embolism, 4% grade III pneumonia |